Company intelligence / Profile preview
NW PharmaTech
London, England, United Kingdomnwpharmatech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NW PharmaTech is advancing multiple clinical programs targeting CNS indications and psychiatric disorders. Its lead program, an oral formulation of cannabidiol developed via OralTransTM technology, is set for late-stage Phase II trials. The company has established strategic joint ventures and employs translational research to overcome traditional bioavailability and delivery challenges associated with natural compounds
- Therapeutic areas
- NeurologyPsychiatry
- Modalities
- Small moleculeBiologicCannabinoid (CBD-based drug formulations)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Satellos Bioscience / Amphotericin B Technologies Inc.; collaborative development and licensing of OralTransTM platform for Oral CBD
Beyond the preview
Go deeper on NW PharmaTech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NW PharmaTech.